Top page > Technology / R&D > SAB / Advisors
Science adviser meeting
Our science adviser meeting functions as a practical strategy meeting of "desirable anticancer drugs" research and development with top scientists in the fields of anticancer drug development.
With Professor D. Von Hoff, the leading authority of cancer clinical research, as chairman, we hold regular meeting (twice a year) to get their experience, technical and practical knowledge, and the latest information.
Member of science adviser meeting
- Daniel D. Von Hoff, M.D., F.A.C.P. (chairman)
- Professor, Arizona National Cancer Center (ex-director), TGen Senior Vice-Director
Former member of FDA Oncology Drug Advisory Committee (ODAC)
Eminent well-known cancer researcher who successively held President of US Cancer Society and President of US Cancer Therapy Society
Far more than 20 years, he engaged in clinical studies involving more than 200 types of anticancer drugs.
He also has practical accomplishment to launch early clinical business.
- Donald W. Kufe, M.D.
- Professor, Department of Medicine, Harvard University
As the Vise Director of Dana-Farber Cancer Institute, he engaged in Phase 1 clinical study as Director and Clinical program reader.
minent well-known cancer researcher who engaged in signal transduction inhibitor, neovascularisation inhibitor, and research and development of cancer vaccine.
- William G. Dunphy, Ph.D.
- Professor, California Institute of Technology, Researcher, Howard Hughes Medical Institute
Eminent well-known researcher as the leading person of cell cycle G2 checkpoint fundamental researches
Adviser
- (Honorary adviser) Yoshio Masui
- Honorary professor, University of Toronto
- Tadashi Matsumoto
- President and CEO, ReqMed Co., Ltd.
- Hideyo Imanishi
- President and CEO, Apios Co., Ltd.
